Pulmonary hypertension is a life-threatening condition characterized by high blood pressure in the pulmonary arteries, leading to heart failure and other complications. Pharmacological agents are the primary mode of treatment for pulmonary hypertension, and new agents are continuously being developed and studied to improve patient outcomes. In this assessment, we review the current literature and analyze clinical trials to evaluate the efficacy of new pharmacological agents in the treatment of pulmonary hypertension. We discuss the potential benefits and limitations of these new agents and provide clinicians and patients with a better understanding of the available treatment options.
HTML PDFShare this article
Journal of Lung Diseases & Treatment received 247 citations as per Google Scholar report
